$ELTX earnings report

Elicio reports Q3 2026 net loss of $(7,979) thousand ($(0.30) per share) as AMPLIFY-7P subgroup analyses inform a planned Phase 3 in adjuvant PDAC. AlphAI read Elicio Therapeutics's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readELTX · Q3 2026 · ended 2026-09-30

Elicio reports Q3 2026 net loss of $(7,979) thousand ($(0.30) per share) as AMPLIFY-7P subgroup analyses inform a planned Phase 3 in adjuvant PDAC

→Mixed quarter

The quarter shows a lower net loss and lower R&D than the prior-year quarter, and the company points to pre-specified subgroup analyses from AMPLIFY-7P. Against that, the primary DFS endpoint was not met in the intent-to-treat population, G&A rose, cash of $30.9 million is guided to fund operations only into the second quarter of 2027, and the company raised capital through an at-the-market program and a July 2026 registered direct offering.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense (Q3 2026)GAAP$4.89M–decrease of $0.1 million
General and administrative expense (Q3 2026)GAAP$3.56M–increase of $0.6 million
Total operating expenses (Q3 2026)GAAP8.45M––
Loss from operations (Q3 2026)GAAP−8.45M––
Total other income (expense), net (Q3 2026)GAAP528K––
Income tax expense (Q3 2026)GAAP−55K––
Net loss (Q3 2026)GAAP−$7.98M––
Comprehensive loss (Q3 2026)GAAP−$7.98M––
Net loss per common share, basic and diluted (Q3 2026)GAAP$(0.30)––
Cash and cash equivalents (as of September 30, 2026)GAAP$30.9M––
Total assets (as of September 30, 2026)GAAP39.60M––
Net proceeds from at-the-market program (Q3 2026)other$4.3M––
Net proceeds from at-the-market program (year to date 2026)otherapproximately $28.6 million––
Net proceeds from registered direct offering (July 2026)otherapproximately $13.6 million––

Capital returns

  • The filing reports no share repurchases or dividends.
  • Capital was raised, not returned: net proceeds of $4.3 million in Q3 2026 and approximately $28.6 million year to date through the at-the-market program.
  • In July 2026 the company raised aggregate net proceeds of approximately $13.6 million in a registered direct offering after deducting placement agents' fees and related offering expenses.

What drove it

  • The company attributes the R&D decrease of $0.1 million primarily to lower clinical trial costs as the Phase 2 study of camupepimut continues and patients moved out of the active dosing phase and into the follow-up phase, partially offset by increased personnel costs.
  • The company attributes the G&A increase of $0.6 million primarily to increased personnel costs and an increase in professional fees.
  • Other income (expense) moved from $(2,038) thousand to 528 thousand in the table; the filing gives no explanation for this change.
  • AMPLIFY-7P pre-specified analyses reported a 49% reduction in risk of recurrence or death in ctDNA-negative patients, a 43% reduction in ctDNA-positive patients and a 41% reduction in patients without prior radiation, as presented at ESMO Congress 2026.
  • A supportive multivariable analysis adjusting for baseline prognostic imbalances estimated a 53% reduction in the hazard of recurrence or death (HR 0.47; p=0.0086) in the trial as described by the company.

Concerns

  • The company states that AMPLIFY-7P did not meet its primary disease-free survival endpoint in the intent-to-treat population.
  • The subgroup benefits are presented as pre-specified analyses that the company says inform patient stratification and dosing, and the company describes the multivariable result as supportive rather than as the primary endpoint result.
  • Cash and cash equivalents of $30.9 million are expected to support operations only into the second quarter of 2027.
  • The company relied on at-the-market sales and a July 2026 registered direct offering to raise capital in 2026, with net proceeds approximately $28.6 million year to date through the at-the-market program.
  • G&A rose from $3,006 thousand to $3,563 thousand year over year, which the company attributes to personnel costs and professional fees.
  • The filing reports no revenue line and no collaboration income, so the company's results reflect only operating expenses and other income.

What to watch

  • Regulatory and development plans for a Phase 3 study of camupepimut in adjuvant PDAC, which the company says the AMPLIFY-7P analyses are intended to inform.
  • Start of the Phase 1 study of camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC, which the company targets for Q4 2026.
  • Phase 2 AMPLIFY-7P clinical and translational findings in a plenary oral presentation and late-breaking poster at SITC 2026, and the preclinical AMP-CpG (ELI-004) poster.
  • Financing activity, given the guided runway into the second quarter of 2027 and continued use of the at-the-market program.
  • Whether the investigator-initiated neoadjuvant Phase 1 study led by Memorial Sloan Kettering Cancer Center produces further data.

Balance sheet and cash flow

  • Cash and cash equivalents: $30.9 million (30,900 thousand) as of September 30, 2026, versus 18,563 thousand as of December 31, 2025. The December 31, 2025 comparison is a fiscal year-end balance, not a prior-year quarter.
  • Total current assets: 34,035 thousand (September 30, 2026) versus 19,311 thousand (December 31, 2025).
  • Total assets: 39,596 thousand (September 30, 2026) versus 25,862 thousand (December 31, 2025).
  • Total liabilities: 20,745 thousand (September 30, 2026) versus 24,226 thousand (December 31, 2025). Current liabilities 9,930 thousand versus 8,110 thousand; long-term liabilities 10,815 thousand versus 16,116 thousand.
  • Total stockholders' equity: 18,851 thousand (September 30, 2026) versus 1,636 thousand (December 31, 2025).
  • Company guidance on liquidity: current cash and cash equivalents are expected to support operations into the second quarter of 2027.
  • The filing does not report operating cash flow, investing cash flow, financing cash flow or free cash flow.

Analysis

Elicio reported a third quarter 2026 GAAP net loss of $(7,979) thousand, or $(0.30) per basic and diluted share, compared with $(10,083) thousand, or $(0.60) per share, in the third quarter of 2025. The reduction is visible in the operating line. R&D expense was $4,889 thousand against $5,039 thousand, a decrease the company ties to lower clinical trial costs as the Phase 2 study moves into follow-up, partly offset by personnel costs. G&A expense rose to $3,563 thousand from $3,006 thousand, which the company attributes to personnel costs and professional fees. Total operating expenses were 8,452 thousand against 8,045 thousand, and other income (expense), net swung to 528 thousand from $(2,038) thousand. The filing does not explain the other income change. No revenue, segment or guidance figures are reported, and the company gives no quarter-over-quarter comparison.

The clinical content is the main element of the release. The company presented pre-specified AMPLIFY-7P analyses at ESMO Congress 2026 showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, a 43% reduction in ctDNA-positive patients and a 41% reduction in patients without prior radiation. The release is explicit that the trial did not meet its primary disease-free survival endpoint in the intent-to-treat population. It also reports a supportive multivariable analysis with an HR of 0.47 (p=0.0086) after adjusting for baseline prognostic imbalances. The company frames these results as informing patient stratification, dosing and the planned Phase 3 design in adjuvant PDAC.

Balance sheet capacity is tighter than the income statement suggests. Cash and cash equivalents were $30.9 million at September 30, 2026, up from 18,563 thousand at December 31, 2025, but the company raised net proceeds of $4.3 million in the quarter and approximately $28.6 million year to date through its at-the-market program, plus approximately $13.6 million in a July 2026 registered direct offering. Total stockholders' equity increased to 18,851 thousand from 1,636 thousand at year-end 2025, and total liabilities declined to 20,745 thousand from 24,226 thousand. The company expects its current cash to fund operations into the second quarter of 2027. The filing does not disclose operating or free cash flow, so the cash consumption rate cannot be read from the release.

The near-term items to track are the Q4 2026 start of a Phase 1 study combining camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC, the SITC 2026 presentations of AMPLIFY-7P data, and the Phase 3 plan in adjuvant PDAC. Because the company guides to a second-quarter 2027 cash horizon, further financing and its terms will matter to shareholders as much as the clinical updates.

Management, verbatim

The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.

Robert Connelly, President and Chief Executive Officer

We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late- stage development and refine our Phase 3 strategy in adjuvant PDAC,

Robert Connelly, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Total revenue or collaboration revenue: no revenue line is reported in the filing.
  • Prior-year and prior-quarter comparisons for total operating expenses, loss from operations, other income (expense), net, net loss, comprehensive loss and EPS: the filing prints no percentage or dollar change for these lines.
  • Prior-year comparison for income tax expense: the table prints a dash for Q3 2025, which is not a reported figure.
  • Prior-quarter (June 30, 2026) figures for every line: the filing gives only Q3 2026 and Q3 2025 comparisons and the September 30 and December 31 balance sheets.
  • Year-to-date (nine months) statements of operations: the filing prints only the three months ended September 30 for the income statement.
  • Operating cash flow, investing cash flow, financing cash flow and free cash flow: not reported.
  • Total debt: no debt line is reported.
  • Share repurchases and dividends: not reported.
  • Guidance on revenue, operating expenses or net loss: none provided beyond the runway statement.
  • Segment data: none reported.
  • Analyst consensus, price targets and share-price reaction: not in the documents and not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ELTX earnings dates

When is Elicio Therapeutics's next earnings date?
AlphAI has no date for ELTX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.